ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
H3 Biomedicine has opened new headquarters and 24,000 sq ft of lab space in Cambridge, Mass. Launched in January, the small-molecule oncology drug firm plans to increase its staff to 70 people over the next year. H3’s scientific founders are Stuart Schreiber and Todd Golub of the Broad Institute of Harvard University and MIT. H3 is backed by the Japanese drug company Eisai, which has pledged up to $200 million in research funding to H3.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter